Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic ...
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor ...
Explore the latest statistics on cutaneous melanoma, including rising incidence rates and declining mortality rates in the ...
Patient-reported outcomes (PROs), which assess symptoms, functional status, and quality of life, had independent prognostic value for overall survival in patients with cancer, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results